Cargando…
Treatment beyond progression with chemo-immunotherapy in an advanced esophageal squamous cell carcinoma patient: a case report
Esophageal cancer is an aggressive and common malignancy in Asian countries. Due to late diagnosis and limited treatments, the prognosis of esophageal cancer is still very poor. Although immune checkpoint inhibitors have become promising second-line treatments for esophageal cancer, there are limite...
Autores principales: | Peng, Ping, Xiao, Yajie, Zhao, Zhikun, Sun, Chao, Wu, Dongfang, Chen, Yuan, Zhang, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798522/ https://www.ncbi.nlm.nih.gov/pubmed/35116347 http://dx.doi.org/10.21037/tcr-21-1395 |
Ejemplares similares
-
Role of Integrin β1 in the progression and chemo-resistance of esophageal squamous cell carcinoma
por: Xie, Ying-Hua, et al.
Publicado: (2022) -
Immunotherapy for Esophageal Squamous Cell Carcinoma
por: Kojima, Takashi, et al.
Publicado: (2017) -
Immune checkpoint inhibitors combined with or without radio(chemo)therapy for locally advanced or recurrent/metastatic esophageal squamous cell carcinoma
por: Zhao, Xiao-Han, et al.
Publicado: (2023) -
Case Report: Therapeutic Response to Chemo-Immunotherapy in an Advanced Large Cell Lung Carcinoma Patient With Low Values of Multiple Predictive Biomarkers
por: Wang, Guihua, et al.
Publicado: (2021) -
Recent Advances in Combination of Immunotherapy and Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
por: Wang, Ruixi, et al.
Publicado: (2022)